Available Therapies for Idiopathic Pulmonary Fibrosis
The two FDA-approved antifibrotic medications—pirfenidone and nintedanib—are the cornerstone pharmacologic therapies for IPF, with nintedanib receiving a conditional recommendation and pirfenidone also supported by guideline evidence 1, 2.
First-Line Antifibrotic Therapy
Nintedanib
- Nintedanib is conditionally recommended for patients with IPF based on the most recent 2022 ATS/ERS/JRS/ALAT guidelines 1
- This intracellular tyrosine kinase inhibitor targets multiple growth factor receptors (VEGF, FGF, PDGF) 2
- The 2015 guidelines demonstrated that nintedanib at 150 mg twice daily reduces FVC decline and acute exacerbations (HR 0.16; 95% CI 0.04-0.70) 2
- Nintedanib has also been globally approved for progressive non-IPF interstitial lung diseases 3
Pirfenidone
- Pirfenidone is the other established antifibrotic agent for IPF treatment 1
- The 2022 guidelines recommend additional research into pirfenidone, indicating ongoing support for its use 1
- Both antifibrotics slow lung function decline but do not reverse existing lung damage 3
Recently Approved Therapy
Nerandomilast
- The FDA recently approved nerandomilast for IPF and progressive pulmonary fibrosis management 3
- This represents the first new approval in approximately a decade beyond pirfenidone and nintedanib
- This phosphodiesterase inhibitor expands the therapeutic armamentarium
What NOT to Use
Contraindicated Combination Therapy
- Clinicians should NOT use the triple combination of N-acetylcysteine, azathioprine, and prednisone (strong recommendation) 2
- This recommendation stems from a trial stopped early for harm, showing clear negative effects on multiple patient-important outcomes 2
Ambrisentan
- Do not use ambrisentan (selective endothelin receptor antagonist) based on guideline recommendations 2
Non-Pharmacologic Therapies
While not the primary focus, supplementary approaches include 4:
- Long-term oxygen therapy
- Lung transplantation (definitive treatment for eligible patients)
- Pulmonary rehabilitation
- Palliative care for cough and dyspnea management
Progressive Pulmonary Fibrosis Beyond IPF
For patients with non-IPF interstitial lung diseases showing progressive pulmonary fibrosis, nintedanib receives a conditional recommendation 1. The 2022 guidelines define progression as radiological, clinical, or physiological worsening within the past year with no alternative explanation, representing a paradigm shift toward treating progressive fibrosis across ILD subtypes.
Clinical Implementation Considerations
The current antifibrotics slow disease progression but have limitations 3, 5:
- Neither medication reverses existing fibrosis
- Neither fully addresses the complex pathophysiology
- Treatment focuses on slowing FVC decline rather than cure
- Adverse effects require monitoring (diarrhea with nintedanib being particularly common)
Common Pitfalls
- Do not continue triple therapy (NAC/azathioprine/prednisone) in patients already receiving it long-term without reassessing the diagnosis—the guidelines specifically note uncertainty about stopping established combination therapy, but the harm signal is clear 2
- Do not assume all endothelin receptor antagonists are equivalent—ambrisentan specifically showed no benefit and potential harm 2
- Do not delay antifibrotic initiation—these medications slow progression but cannot reverse damage already present